{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:55:15Z","timestamp":1761058515031},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,8,26]],"date-time":"2006-08-26T00:00:00Z","timestamp":1156550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,10,4]]},"DOI":"10.1007\/s00228-006-0186-z","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T17:22:15Z","timestamp":1156526535000},"page":"793-803","source":"Crossref","is-referenced-by-count":15,"title":["Current and novel approaches to the drug therapy of obesity"],"prefix":"10.1007","volume":"62","author":[{"given":"Jean-Philippe","family":"Chaput","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,8,26]]},"reference":[{"key":"186_CR1","volume-title":"Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic","author":"World Health Organization","year":"1998","unstructured":"World Health Organization (1998) Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic. World Health Organization, Geneva"},{"key":"186_CR2","first-page":"S76","volume":"19","author":"JP Despr\u00e9s","year":"1995","unstructured":"Despr\u00e9s JP, Lemieux S, Lamarche B et al (1995) The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord 19:S76\u2013S86","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR3","first-page":"205","volume-title":"Clinical Obesity","author":"LF Gaal Van","year":"1998","unstructured":"Van Gaal LF, Mertens IL (1998) Effects of obesity on cardiovascular system and blood pressure control, digestive disease and cancer. In: Kopelman P, Stock M (eds) Clinical Obesity. Blackwell Science, Oxford, pp 205\u2013225"},{"key":"186_CR4","first-page":"875","volume-title":"Handbook of Obesity","author":"LF Gaal Van","year":"1998","unstructured":"Van Gaal LF (1998) Dietary treatment of obesity. In: Bray GA, Bouchard C, James WPTD (eds) Handbook of Obesity. Marcel Dekker, New York, pp 875\u2013890"},{"issue":"Suppl 1","key":"186_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.ijo.0800795","volume":"23","author":"AJ Scheen","year":"1999","unstructured":"Scheen AJ, Lefebvre PJ (1999) Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 23(Suppl 1):47\u201353","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1210\/jc.2003-030151","volume":"88","author":"DS Weigle","year":"2003","unstructured":"Weigle DS (2003) Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 88:2462\u20132469","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","volume":"6","author":"BJ Rolls","year":"1998","unstructured":"Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS (1998) Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 6:1\u201311","journal-title":"Obes Res"},{"issue":"Suppl 1","key":"186_CR8","first-page":"S30","volume":"22","author":"A Astrup","year":"1998","unstructured":"Astrup A, Hansen DL, Lundsgaard C, Toubro S (1998) Sibutramine and energy balance. Int J Obes Relat Metab Disord 22(Suppl 1):S30\u2013S35","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.ijo.0801059","volume":"23","author":"DL Hansen","year":"1999","unstructured":"Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A (1999) The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 23:1016\u20131024","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0889-8529(03)00066-5","volume":"32","author":"M Thearle","year":"2003","unstructured":"Thearle M, Aronne LJ (2003) Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 32:1005\u20131024","journal-title":"Endocrinol Metab Clin North Am"},{"key":"186_CR11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R, Li SK, Lau DC (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27:1437\u20131446","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4158\/EP.11.5.308","volume":"11","author":"A Gursoy","year":"2005","unstructured":"Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N (2005) Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension. Endocr Pract 11:308\u2013312","journal-title":"Endocr Pract"},{"key":"186_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","volume":"7","author":"DS Bach","year":"1999","unstructured":"Bach DS, Rissanen AM, Mendel CM et al (1999) Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 7:363\u2013369","journal-title":"Obes Res"},{"key":"186_CR14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130050001","volume":"147","author":"LM Schuh","year":"2000","unstructured":"Schuh LM, Schuster CR, Hopper JA, Mendel CM (2000) Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology 147:339\u2013346","journal-title":"Psychopharmacology"},{"key":"186_CR15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.ijo.0801677","volume":"25","author":"S B\u00e9rub\u00e9-Parent","year":"2001","unstructured":"B\u00e9rub\u00e9-Parent S, Prud\u2019homme D, St-Pierre S, Doucet E, Tremblay A (2001) Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes 25:1144\u20131153","journal-title":"Int J Obes"},{"key":"186_CR16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M et al (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 281:235\u2013242","journal-title":"JAMA"},{"key":"186_CR17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","volume":"16","author":"JH Zavoral","year":"1998","unstructured":"Zavoral JH (1998) Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 16:2013\u20132017","journal-title":"J Hypertens"},{"key":"186_CR18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","volume":"8","author":"TA Wadden","year":"2000","unstructured":"Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM (2000) Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8:431\u2013437","journal-title":"Obes Res"},{"key":"186_CR19","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1210\/jc.2004-0341","volume":"89","author":"J Korner","year":"2004","unstructured":"Korner J, Aronne LJ (2004) Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 89:2616\u20132621","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0031-9384(98)00170-X","volume":"65","author":"CM Williams","year":"1998","unstructured":"Williams CM, Rogers PJ, Kirkham TC (1998) Hyperphagia in pre-fed rats following oral \u03949-THC. Physiol Behav 65:343\u2013346","journal-title":"Physiol Behav"},{"key":"186_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0195-6663(88)80017-5","volume":"11","author":"RW Foltin","year":"1988","unstructured":"Foltin RW, Fischman MW, Byrne MF (1988) Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1\u201314","journal-title":"Appetite"},{"key":"186_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","volume":"112","author":"D Cota","year":"2003","unstructured":"Cota D, Marsicano G, Tschop M et al (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423\u2013431","journal-title":"J Clin Invest"},{"key":"186_CR23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","volume":"350","author":"M Rinaldi-Carmona","year":"1994","unstructured":"Rinaldi-Carmona M, Barth F, Heaulme M et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240\u2013244","journal-title":"FEBS Lett"},{"key":"186_CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0024-3205(98)00322-1","volume":"63","author":"G Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63:113\u2013117","journal-title":"Life Sci"},{"key":"186_CR25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(03)01343-8","volume":"462","author":"AL Hildebrandt","year":"2003","unstructured":"Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003) Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462:125\u2013132","journal-title":"Eur J Pharmacol"},{"key":"186_CR26","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","volume":"284","author":"C Ravinet Trillou","year":"2003","unstructured":"Ravinet Trillou C, Arnone M, Delgorge C et al (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345\u2013353","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"186_CR27","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despr\u00e9s","year":"2005","unstructured":"Despr\u00e9s JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121\u20132134","journal-title":"N Engl J Med"},{"key":"186_CR28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-6773(75)91684-3","volume":"15","author":"EL Abel","year":"1975","unstructured":"Abel EL (1975) Cannabis: effects on hunger and thirst. Behav Biol 15:255\u2013281","journal-title":"Behav Biol"},{"key":"186_CR29","unstructured":"SPG Media Limited. Rimonabant selective CB1 endocannabinoid receptor antagonist for the treatment of obesity. http:\/\/www.drugdevelopment-technology.com\/projects\/rimonabant\/ (accessed July 2006)"},{"key":"186_CR30","unstructured":"Anthenelli RM, Despr\u00e9s JP (2004) Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight\/Obese Patients with Dyslipidemia). Session Late Breaking Clinical Trials II Annual Scientific Session, New Orleans, LA"},{"key":"186_CR31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425\u2013432","journal-title":"Nature"},{"key":"186_CR32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","volume":"269","author":"JL Halaas","year":"1995","unstructured":"Halaas JL, Gajiwala KS, Maffei M et al (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543\u2013546","journal-title":"Science"},{"key":"186_CR33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","volume":"341","author":"IS Farooqi","year":"1999","unstructured":"Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879\u2013884","journal-title":"N Engl J Med"},{"key":"186_CR34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/382250a0","volume":"382","author":"RS Ahima","year":"1996","unstructured":"Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier JS (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250\u2013252","journal-title":"Nature"},{"key":"186_CR35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1126\/science.280.5368.1378","volume":"280","author":"SC Woods","year":"1998","unstructured":"Woods SC, Seeley RJ, Porte D, Schwartz MW (1998) Signals that regulate food intake and energy homeostasis. Science 280:1378\u20131383","journal-title":"Science"},{"key":"186_CR36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB, Greenberg AS, Fujioka D et al (1999) Recombinant leptin for weight loss in obese and lean adults. JAMA 282:1568\u20131575","journal-title":"JAMA"},{"key":"186_CR37","first-page":"4033","volume":"85","author":"CS Mantzoros","year":"2000","unstructured":"Mantzoros CS, Flier JS (2000) Editorial: leptin as a therapeutic agent-trials and tribulations. J Clin Endocrinol Metab 85:4033\u20134039","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR38","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","volume":"85","author":"CJ Hukshorn","year":"2000","unstructured":"Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 85:4003\u20134009","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR39","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.289.14.1826","volume":"289","author":"MP Ettinger","year":"2003","unstructured":"Ettinger MP, Littlejohn TW, Schwartz SL et al (2003) Recombinant variant of ciliary neutrophic factor for weight loss in obese adults. JAMA 289:1826\u20131832","journal-title":"JAMA"},{"key":"186_CR40","unstructured":"Regeneron Pharmaceuticals. Axokine. Press release. Regeneron announces results of phase III obesity study (3\/31\/2003) and Regeneron moving forward with AXOKINE phase III program for treatment of obesity (9\/9\/2003). http:\/\/www.regeneron.com\/company\/press_detail.asp?v_c_id=182 (accessed July 2006)"},{"key":"186_CR41","unstructured":"Glicklich A, Bays H, Russell T, Weinstein S, Hollander P (2003) AXOKINE promotes weight loss in overweight and obese patients with type 2 diabetes mellitus. Poster Abstract 471-P. NAASO\u2019s 2003 Annual Meeting. Ft. Lauderdale, FL"},{"key":"186_CR42","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656\u2013660","journal-title":"Nature"},{"key":"186_CR43","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/endo.142.10.8490","volume":"142","author":"TL Horvath","year":"2001","unstructured":"Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M (2001) Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 142:4163\u20134169","journal-title":"Endocrinology"},{"key":"186_CR44","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/diabetes.50.8.1714","volume":"50","author":"DE Cummings","year":"2001","unstructured":"Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714\u20131719","journal-title":"Diabetes"},{"key":"186_CR45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF03351037","volume":"24","author":"M Tsch\u00f6p","year":"2001","unstructured":"Tsch\u00f6p M, Wawarta R, Riepl RL et al (2001) Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24:19\u201321","journal-title":"J Endocrinol Invest"},{"key":"186_CR46","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jcem.86.12.8111","volume":"86","author":"AM Wren","year":"2001","unstructured":"Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR47","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJMoa012908","volume":"346","author":"DE Cummings","year":"2002","unstructured":"Cummings DE, Weigle DS, Frayo RS et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623\u20131630","journal-title":"N Engl J Med"},{"key":"186_CR48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/oby.2004.43","volume":"12","author":"R Stoeckli","year":"2004","unstructured":"Stoeckli R, Chanda R, Langer I, Keller U (2004) Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 12:346\u2013350","journal-title":"Obes Res"},{"key":"186_CR49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1054\/npep.2002.0895","volume":"36","author":"S Bi","year":"2002","unstructured":"Bi S, Moran TH (2002) Actions of CCK in the controls of food intake and body weight: lessons from the CCK-A receptor deficient OLETF rat. Neuropeptides 36:171\u2013181","journal-title":"Neuropeptides"},{"key":"186_CR50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1568026033452258","volume":"3","author":"JR Szewczyk","year":"2003","unstructured":"Szewczyk JR, Laudeman C (2003) CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr Top Med Chem 3:837\u2013854","journal-title":"Curr Top Med Chem"},{"key":"186_CR51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000126831","volume":"61","author":"RJ Lieverse","year":"1995","unstructured":"Lieverse RJ, Jansen JB, Masclee AM, Lamers CB (1995) Effects of somatostatin on human satiety. Neuroendocrinology 61:112\u2013116","journal-title":"Neuroendocrinology"},{"key":"186_CR52","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K et al (2003) Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 88:2586\u20132592","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.ijo.0802561","volume":"28","author":"PA Velasquez-Mieyer","year":"2004","unstructured":"Velasquez-Mieyer PA, Umpierrez GE, Lustig RH et al (2004) Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord 28:330\u2013333","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0095-4543(03)00043-5","volume":"30","author":"J Albu","year":"2003","unstructured":"Albu J, Raja-Khan N (2003) The management of the obese diabetic patient. Clin Office Pract 30:465\u2013491","journal-title":"Clin Office Pract"},{"key":"186_CR55","doi-asserted-by":"crossref","unstructured":"DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A (2004) Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Program and abstracts of the 64th Scientific Sessions of the American Diabetes Association, Orlando, FL. Late breaking abstract 6","DOI":"10.2337\/diacare.28.5.1092"},{"key":"186_CR56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bjp.0705397","volume":"140","author":"J Sturis","year":"2003","unstructured":"Sturis J, Gotfredsen CF, Romer J et al (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123\u2013132","journal-title":"Br J Pharmacol"},{"key":"186_CR57","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","volume":"25","author":"B Ahren","year":"2002","unstructured":"Ahren B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 25:869\u2013875","journal-title":"Diabetes Care"},{"key":"186_CR58","first-page":"1533","volume":"83","author":"R Chakrabarti","year":"2002","unstructured":"Chakrabarti R, Rajagopalan R (2002) Diabetes and insulin resistance associated disorders: disease and therapy. Curr Sci 83:1533\u20131538","journal-title":"Curr Sci"},{"key":"186_CR59","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","volume":"418","author":"RL Batterham","year":"2002","unstructured":"Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY 3\u201336 physiologically inhibits food intake. Nature 418:650\u2013653","journal-title":"Nature"},{"key":"186_CR60","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2003-030421","volume":"88","author":"MA Cohen","year":"2003","unstructured":"Cohen MA, Ellis SM, Le Roux CW et al (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696\u20134701","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1100\/tsw.2001.449","volume":"18","author":"AA Young","year":"2001","unstructured":"Young AA (2001) Amylin as a neuroendocrine hormone. Scientific World J 18:24","journal-title":"Scientific World J"},{"key":"186_CR62","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","volume":"12","author":"D Maggs","year":"2003","unstructured":"Maggs D, Shen L, Brown D, Kolterman O, Weyer C (2003) Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 12:1638\u20131642","journal-title":"Metabolism"},{"key":"186_CR63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","volume":"5","author":"P Hollander","year":"2003","unstructured":"Hollander P, Ratner R, Fineman M et al (2003) Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 5:408\u2013414","journal-title":"Diabetes Obes Metab"},{"key":"186_CR64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","volume":"12","author":"P Hollander","year":"2004","unstructured":"Hollander P, Maggs DG, Ruggles JA et al (2004) Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12:661\u2013668","journal-title":"Obes Res"},{"key":"186_CR65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1043-2760(00)00272-1","volume":"11","author":"DE Moller","year":"2000","unstructured":"Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212\u2013217","journal-title":"Trends Endocrinol Metab"},{"key":"186_CR66","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI1235","volume":"101","author":"A Okuno","year":"1998","unstructured":"Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354\u20131361","journal-title":"J Clin Invest"},{"key":"186_CR67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1677\/joe.0.1630033","volume":"163","author":"CP Sewter","year":"1999","unstructured":"Sewter CP, Digby JE, Blows F, Prins J, O\u2019Rahilly S (1999) Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 163:33\u201338","journal-title":"J Endocrinol"},{"key":"186_CR68","first-page":"2126","volume":"84","author":"Z Orban","year":"1999","unstructured":"Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP (1999) The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 84:2126\u20132133","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR69","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.274.5291.1377","volume":"274","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377\u20131379","journal-title":"Science"},{"key":"186_CR70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ijo.0800770","volume":"22","author":"V Mohamed-Ali","year":"1998","unstructured":"Mohamed-Ali V, Pinkney JH, Coppack SW (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145\u20131158","journal-title":"Int J Obes Relat Metab Disord"},{"key":"186_CR71","first-page":"3338","volume":"85","author":"JP Bastard","year":"2000","unstructured":"Bastard JP, Jardel C, Bruckert E et al (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338\u20133342","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0006-291X(02)00230-9","volume":"293","author":"K Wallenius","year":"2002","unstructured":"Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO (2002) Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560\u2013565","journal-title":"Biochem Biophys Res Commun"},{"key":"186_CR73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75\u201379","journal-title":"Nat Med"},{"key":"186_CR74","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/oby.2003.137","volume":"11","author":"K Azuma","year":"2003","unstructured":"Azuma K, Katsukawa F, Oguchi S et al (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11:997\u20131001","journal-title":"Obes Res"},{"key":"186_CR75","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/diabetes.52.7.1611","volume":"52","author":"SR Smith","year":"2003","unstructured":"Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G (2003) A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52:1611\u20131618","journal-title":"Diabetes"},{"key":"186_CR76","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1210\/jcem.87.5.8627","volume":"87","author":"PG McTernan","year":"2002","unstructured":"McTernan PG, McTernan CL, Chetty R et al (2002) Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407","journal-title":"J Clin Endocrinol Metab"},{"key":"186_CR77","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/diabetes.50.10.2199","volume":"50","author":"DB Savage","year":"2001","unstructured":"Savage DB, Sewter CP, Klenk ES et al (2001) Resistin\/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199\u20132202","journal-title":"Diabetes"},{"key":"186_CR78","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.0000084503.91330.49","volume":"108","author":"S Verma","year":"2003","unstructured":"Verma S, Li SH, Wang CH et al (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736\u2013740","journal-title":"Circulation"},{"key":"186_CR79","first-page":"RA55","volume":"9","author":"J Beltowski","year":"2003","unstructured":"Beltowski J (2003) Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 9:RA55\u2013RA61","journal-title":"Med Sci Monit"},{"key":"186_CR80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79\u201383","journal-title":"Biochem Biophys Res Commun"},{"key":"186_CR81","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","volume":"20","author":"K Hotta","year":"2000","unstructured":"Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595\u20131599","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"186_CR82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0895-7061(02)03197-7","volume":"16","author":"M Adamczak","year":"2003","unstructured":"Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72\u201375","journal-title":"Am J Hypertens"},{"key":"186_CR83","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1161\/01.CIR.100.25.2473","volume":"100","author":"N Ouchi","year":"1999","unstructured":"Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473\u20132476","journal-title":"Circulation"},{"key":"186_CR84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/01.ATV.0000048856.22331.50","volume":"23","author":"M Kumada","year":"2003","unstructured":"Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85\u201389","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"186_CR85","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941\u2013946","journal-title":"Nat Med"},{"key":"186_CR86","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/90992","volume":"7","author":"AH Berg","year":"2002","unstructured":"Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2002) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947\u2013953","journal-title":"Nat Med"},{"key":"186_CR87","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","volume":"8","author":"T Yamauchi","year":"2002","unstructured":"Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288\u20131295","journal-title":"Nat Med"},{"key":"186_CR88","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1172\/JCI14120","volume":"108","author":"TP Combs","year":"2001","unstructured":"Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875\u20131881","journal-title":"J Clin Invest"},{"key":"186_CR89","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","volume":"307","author":"A Fukuhara","year":"2005","unstructured":"Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426\u2013443","journal-title":"Science"},{"key":"186_CR90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cmet.2004.12.002","volume":"1","author":"J Phan","year":"2005","unstructured":"Phan J, Reue K (2005) Lipin, a lipodystrophy and obesity gene. Cell Metabolism 1:73\u201383","journal-title":"Cell Metabolism"},{"key":"186_CR91","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1073\/pnas.022634399","volume":"99","author":"TA Huffman","year":"2002","unstructured":"Huffman TA, Mothe-Satney I, Lawrence JC Jr (2002) Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 99:1047\u20131052","journal-title":"Proc Natl Acad Sci USA"},{"key":"186_CR92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661\u2013671","journal-title":"Nature"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0186-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0186-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0186-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:32Z","timestamp":1558702292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0186-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,26]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10,4]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0186-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,26]]}}}